154 related articles for article (PubMed ID: 18622874)
1. The influence of crystal habit on the prediction of dry powder inhalation formulation performance using the cohesive-adhesive force balance approach.
Hooton JC; Jones MD; Harris H; Shur J; Price R
Drug Dev Ind Pharm; 2008 Sep; 34(9):974-83. PubMed ID: 18622874
[TBL] [Abstract][Full Text] [Related]
2. Predicting the behavior of novel sugar carriers for dry powder inhaler formulations via the use of a cohesive-adhesive force balance approach.
Hooton JC; Jones MD; Price R
J Pharm Sci; 2006 Jun; 95(6):1288-97. PubMed ID: 16637052
[TBL] [Abstract][Full Text] [Related]
3. The cohesive-adhesive balances in dry powder inhaler formulations I: Direct quantification by atomic force microscopy.
Begat P; Morton DA; Staniforth JN; Price R
Pharm Res; 2004 Sep; 21(9):1591-7. PubMed ID: 15497684
[TBL] [Abstract][Full Text] [Related]
4. The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics.
Begat P; Morton DA; Staniforth JN; Price R
Pharm Res; 2004 Oct; 21(10):1826-33. PubMed ID: 15553229
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the cohesion-adhesion balance approach to colloidal probe atomic force microscopy and the measurement of Hansen partial solubility parameters by inverse gas chromatography for the prediction of dry powder inhalation performance.
Jones MD; Buckton G
Int J Pharm; 2016 Jul; 509(1-2):419-430. PubMed ID: 27265314
[TBL] [Abstract][Full Text] [Related]
6. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
[TBL] [Abstract][Full Text] [Related]
7. An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances.
Jones MD; Harris H; Hooton JC; Shur J; King GS; Mathoulin CA; Nichol K; Smith TL; Dawson ML; Ferrie AR; Price R
Eur J Pharm Biopharm; 2008 Jun; 69(2):496-507. PubMed ID: 18191553
[TBL] [Abstract][Full Text] [Related]
8. An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces.
Jones MD; Hooton JC; Dawson ML; Ferrie AR; Price R
Pharm Res; 2008 Feb; 25(2):337-48. PubMed ID: 17952568
[TBL] [Abstract][Full Text] [Related]
9. The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations.
Price R; Young PM; Edge S; Staniforth JN
Int J Pharm; 2002 Oct; 246(1-2):47-59. PubMed ID: 12270608
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of dry powder inhaler formulations using atomic force microscopy.
Weiss C; McLoughlin P; Cathcart H
Int J Pharm; 2015 Oct; 494(1):393-407. PubMed ID: 26302859
[TBL] [Abstract][Full Text] [Related]
11. Formulation pre-screening of inhalation powders using computational atom-atom systematic search method.
Ramachandran V; Murnane D; Hammond RB; Pickering J; Roberts KJ; Soufian M; Forbes B; Jaffari S; Martin GP; Collins E; Pencheva K
Mol Pharm; 2015 Jan; 12(1):18-33. PubMed ID: 25380027
[TBL] [Abstract][Full Text] [Related]
12. Investigation into the influence of primary crystallization conditions on the mechanical properties and secondary processing behaviour of fluticasone propionate for carrier based dry powder inhaler formulations.
Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
Pharm Res; 2012 Apr; 29(4):994-1006. PubMed ID: 22161310
[TBL] [Abstract][Full Text] [Related]
13. Influence of crystal form of ipratropium bromide on micronisation and aerosolisation behaviour in dry powder inhaler formulations.
Shur J; Kubavat HA; Ruecroft G; Hipkiss D; Price R
J Pharm Pharmacol; 2012 Sep; 64(9):1326-36. PubMed ID: 22881444
[TBL] [Abstract][Full Text] [Related]
14. The effect of budesonide particle mass on drug particle detachment from carrier crystals in adhesive mixtures during inhalation.
Dickhoff BH; Ellison MJ; de Boer AH; Frijlink HW
Eur J Pharm Biopharm; 2002 Sep; 54(2):245-8. PubMed ID: 12191698
[TBL] [Abstract][Full Text] [Related]
15. In vitro investigation of drug particulates interactions and aerosol performance of pressurised metered dose inhalers.
Traini D; Young PM; Rogueda P; Price R
Pharm Res; 2007 Jan; 24(1):125-35. PubMed ID: 17103336
[TBL] [Abstract][Full Text] [Related]
16. Dry powder aerosol delivery systems: current and future research directions.
Chan HK
J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
[TBL] [Abstract][Full Text] [Related]
18. Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method.
Lohrmann M; Kappl M; Butt HJ; Urbanetz NA; Lippold BC
Eur J Pharm Biopharm; 2007 Sep; 67(2):579-86. PubMed ID: 17418548
[TBL] [Abstract][Full Text] [Related]
19. Effect of processing history on the surface interfacial properties of budesonide in carrier-based dry-powder inhalers.
Shur J; Pitchayajittipong C; Rogueda P; Price R
Ther Deliv; 2013 Aug; 4(8):925-37. PubMed ID: 23919472
[TBL] [Abstract][Full Text] [Related]
20. Dry powder inhaler formulation.
Telko MJ; Hickey AJ
Respir Care; 2005 Sep; 50(9):1209-27. PubMed ID: 16122404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
